Across TCGA pan-cancer cohorts, VPS13A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated VPS13A data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher VPS13A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated VPS13A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where VPS13A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.914	0.550	.013	18	view →
GBM	OS	Median	All	0.217	0.519	.010	11	view →
PDAC	OS	Median	All	0.537	0.313	.018	10	view →
LUAD	OS	Tertile	II,III,IV	0.436	1.000	.003	8	view →
HNSC	DFS	Median	III,IV	0.712	0.493	.015	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: VPS13A tumor-vs-normal RNA expression · all VPS13A data types